Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2020

View Archived Issues

SWI/SNF mutations can lead to gain of function

Lactose tolerance may be Red Herring

CXCR3 is a potential therapeutic target in pulmonary hypertension

Midatech presents phase I data for MTX-110 in diffuse intrinsic pontine glioma

Hinova Pharmaceuticals divulges new BRD4 and AR dual inhibitors

Betta Pharmaceuticals patents EGFR mutant inhibitors

Chinese researchers present new MAPK inhibitors

Positive interim data presented from phase III SHORELINE study of zuranolone in MDD

Yichang Humanwell Pharmaceutical synthesizes kappa-opioid receptor agonists

In extracellular space, intracellular protein fights sepsis

Intellia receives authorization to initiate first-in-human study of NTLA-2001 in the U.K.

Phanes Therapeutics discloses anti-claudin 18.2 CARs

NGM targets new immuno-oncology development candidate NGM-707 to enter clinic next year

Global phase II study of OT-101 for COVID-19 cleared for enrollment in Argentina

Approval of phase I study of bacTRL-Spike vaccine for prevention of COVID-19

VLS-101 enters phase II trial in previously treated solid tumors

CHRM3 unveiled as a therapeutic target in NSCLC

Discovery of novel highly potent ghrelin receptor full agonists

DeltaF508 CFTR cystic fibrosis models generated in Collaborative Cross mice

miRNA-646 and miRNA-4739 identified as schizophrenia markers

DSMB recommends progression of phase II trial of MAT-2203 for cryptococcal meningitis

New substudy evaluates Treadwell's CFI-400945 in metastatic CRPC

Aptinyx reports promising phase II data on NYX-783 in PTSD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...